GlassScriptPhysician profile
Candra Sonnie Smith
NPI 1851945638
$6,465.75
in general payments reported to CMS, 2019-2025
21 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,165 · 2022: $1,679 · 2023: $1,419 · 2024: $889 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,622.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,351.64 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $839.80 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $702.96 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $596.66 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $476.36 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $437.89 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $366.07 | 2021-2022 | |
| Indivior INC. | $358.07 | 2021-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $239.52 | 2022-2024 | Trintellix |
| Corium, LLC | $220.70 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $220.20 | 2021-2023 | Austedo Xr, Austedo |
| Lundbeck LLC | $158.87 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.30 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $118.24 | 2022 | |
| Vanda Pharmaceuticals INC. | $85.40 | 2022-2023 | Fanapt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $36.44 | 2022 | |
| Medtronic, INC. | $23.65 | 2023 | Ellipsys Vascular Access System |
| Luye Pharma (USA) LTD. | $22.10 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $20.22 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $18.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.78 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candra Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.